
SGLT-2 inhibitors, proven through trials and real-world data, offer significant cardiovascular benefits beyond antidiabetic effects, aiding in preventing CVD in DM patients. Their efficacy extends to nondiabetic CVD and renal disease. Despite ongoing research into their molecular mechanisms, their role in CVD prevention is crucial for diverse medical specialists. This review presents evidence supporting their rational clinical use.
Like
Save
Share